Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

durvalumab

Details

Files
Generic Name:
durvalumab
Project Status:
Active
Therapeutic Area:
limited-stage small cell lung cancer (LS-SCLC)
Manufacturer:
AstraZeneca Canada Inc.
Call for patient/clinician input open:
Brand Name:
Imfinzi
Project Line:
Reimbursement Review
Project Number:
PC0389-000
Call for patient/clinician input closed:
Tumour Type:
Lung
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Imfinzi (durvalumab) is currently under review by Health Canada for the following proposed indication: for the treatment of patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT).
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​Imfinzi (durvalumab) is currently under review by Health Canada for the following proposed indication: for the treatment of patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT).
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input openOctober 02, 2024
Call for patient/clinician input closedNovember 25, 2024
Submission receivedNovember 15, 2024
Submission acceptedNovember 29, 2024
Review initiatedDecember 02, 2024
Draft CADTH review report(s) provided to sponsor for commentFebruary 24, 2025
Deadline for sponsors commentsMarch 05, 2025
CADTH review report(s) and responses to comments provided to sponsorMarch 28, 2025
Expert committee meeting (initial)April 09, 2025
Draft recommendation issued to sponsorApril 23, 2025
To
April 25, 2025
Draft recommendation posted for stakeholder feedbackMay 01, 2025
End of feedback periodMay 15, 2025

Files

Patient and Clinician Group input View PDF
Last Updated : December 17, 2024